Is Roivant Sciences Ltd. (ROIV) a Buy, Sell, or Hold?
Roivant Sciences Ltd.
NASDAQ:ROIV
$34.91 USD
$0.4 (1.16%)
- Volume
- 4.05M
- Average Volume
- 6.06M
- Market Capitalization
- $25.11B
- P/E Ratio
- -77.58
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $37.00
- Year Low
- $10.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.37
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
80
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
209
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 73.71M
ROIV Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
ROIV Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Gline Matthew | director, officer: CEO | 2026-06-30 | F-InKind | 35.39 | 2026-07-02 |
| Fitzgerald Meghan | director | 2026-06-30 | M-Exempt | 8.8 | 2026-07-02 |
| Fitzgerald Meghan | director | 2026-06-30 | S-Sale | 34.9 | 2026-07-02 |
| Fitzgerald Meghan | director | 2026-06-30 | M-Exempt | 8.8 | 2026-07-02 |
| Torti Frank | officer: President and Vant Chair | 2026-06-30 | F-InKind | 35.39 | 2026-07-02 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-30 | F-InKind | 35.39 | 2026-07-02 |
| Epperly Melissa B, | director | 2026-06-29 | M-Exempt | 4.46 | 2026-07-01 |
| Epperly Melissa B, | director | 2026-06-29 | M-Exempt | 4.46 | 2026-07-01 |
| Epperly Melissa B, | director | 2026-06-29 | S-Sale | 34.32 | 2026-07-01 |
| Epperly Melissa B, | director | 2026-06-29 | S-Sale | 34.71 | 2026-07-01 |
| MANCHESTER KEITH S | director | 2026-06-26 | S-Sale | 33.92 | 2026-06-30 |
| MANCHESTER KEITH S | director | 2026-06-26 | S-Sale | 34.07 | 2026-06-30 |
| MANCHESTER KEITH S | director | 2026-06-29 | S-Sale | 34.44 | 2026-06-30 |
| MANCHESTER KEITH S | director | 2026-06-29 | S-Sale | 34.59 | 2026-06-30 |
| MANCHESTER KEITH S | director | 2026-06-30 | S-Sale | 35.28 | 2026-06-30 |
| MANCHESTER KEITH S | director | 2026-06-30 | S-Sale | 35.45 | 2026-06-30 |
| Gold Daniel Allen | director | 2026-06-26 | S-Sale | 33.92 | 2026-06-30 |
| Gold Daniel Allen | director | 2026-06-26 | S-Sale | 34.07 | 2026-06-30 |
| Gold Daniel Allen | director | 2026-06-29 | S-Sale | 34.44 | 2026-06-30 |
| Gold Daniel Allen | director | 2026-06-29 | S-Sale | 34.59 | 2026-06-30 |
| Gold Daniel Allen | director | 2026-06-30 | S-Sale | 35.28 | 2026-06-30 |
| QVT Financial LP | other: Director by Deputization | 2026-06-26 | S-Sale | 33.92 | 2026-06-30 |
| QVT Financial LP | other: Director by Deputization | 2026-06-26 | S-Sale | 34.07 | 2026-06-30 |
| QVT Financial LP | other: Director by Deputization | 2026-06-29 | S-Sale | 34.44 | 2026-06-30 |
| QVT Financial LP | other: Director by Deputization | 2026-06-29 | S-Sale | 34.59 | 2026-06-30 |
| QVT Financial LP | other: Director by Deputization | 2026-06-30 | S-Sale | 35.28 | 2026-06-30 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-26 | M-Exempt | 3.85 | 2026-06-29 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-25 | S-Sale | 34.13 | 2026-06-29 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-26 | S-Sale | 34.08 | 2026-06-29 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-25 | M-Exempt | 3.85 | 2026-06-29 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-06-26 | M-Exempt | 3.85 | 2026-06-29 |
| Venker Eric | officer: President & Immunovant CEO | 2026-06-24 | M-Exempt | 3.85 | 2026-06-26 |
| Venker Eric | officer: President & Immunovant CEO | 2026-06-24 | M-Exempt | 3.85 | 2026-06-26 |
| Venker Eric | officer: President & Immunovant CEO | 2026-06-24 | S-Sale | 33.05 | 2026-06-26 |
| Venker Eric | officer: President & Immunovant CEO | 2026-06-24 | S-Sale | 33.51 | 2026-06-26 |
| Pulik Richard | officer: CFO | 2026-06-20 | F-InKind | 31.43 | 2026-06-23 |
| Humes Jennifer | officer: Chief Accounting Officer | 2026-06-20 | F-InKind | 31.43 | 2026-06-23 |
| Venker Eric | officer: President & Immunovant CEO | 2026-05-22 | M-Exempt | 3.85 | 2026-05-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-05-22 | M-Exempt | 3.85 | 2026-05-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-05-22 | S-Sale | 30.27 | 2026-05-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-05-20 | F-InKind | 32.41 | 2026-05-22 |
| Pulik Richard | officer: CFO | 2026-05-20 | F-InKind | 32.41 | 2026-05-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-04-20 | M-Exempt | 3.85 | 2026-04-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-04-20 | M-Exempt | 3.85 | 2026-04-22 |
| Venker Eric | officer: President & Immunovant CEO | 2026-04-20 | S-Sale | 29.59 | 2026-04-22 |
| Pulik Richard | officer: CFO | 2026-04-20 | A-Award | 0 | 2026-04-22 |
| Pulik Richard | officer: CFO | 2026-04-20 | A-Award | 29.08 | 2026-04-22 |
| Humes Jennifer | officer: Chief Accounting Officer | 2026-04-20 | A-Award | 0 | 2026-04-22 |
| Humes Jennifer | officer: Chief Accounting Officer | 2026-04-20 | A-Award | 29.08 | 2026-04-22 |
| Oren Ilan | director | 2026-04-17 | A-Award | 0 | 2026-04-21 |
| Oren Ilan | director | 2026-04-17 | F-InKind | 29.83 | 2026-04-21 |
| Epperly Melissa B, | director | 2026-04-17 | A-Award | 0 | 2026-04-21 |
| MOMTAZEE JAMES C | director | 2026-04-17 | A-Award | 0 | 2026-04-21 |
| MOMTAZEE JAMES C | director | 2026-04-17 | F-InKind | 29.83 | 2026-04-21 |
| Gline Matthew | director, officer: CEO | 2026-04-16 | S-Sale | 29.16 | 2026-04-20 |
| Humes Jennifer | officer: Chief Accounting Officer | 2026-04-08 | S-Sale | 28.37 | 2026-04-10 |
| Torti Frank | officer: President and Vant Chair | 2026-03-31 | F-InKind | 27.7 | 2026-04-02 |
| Gline Matthew | director, officer: CEO | 2026-03-30 | M-Exempt | 12.68 | 2026-04-01 |
| Gline Matthew | director, officer: CEO | 2026-03-30 | F-InKind | 26.41 | 2026-04-01 |
| Gline Matthew | director, officer: CEO | 2026-03-31 | F-InKind | 27.7 | 2026-04-01 |
| Gline Matthew | director, officer: CEO | 2026-03-30 | M-Exempt | 0 | 2026-04-01 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-03-30 | M-Exempt | 12.68 | 2026-04-01 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-03-30 | F-InKind | 26.41 | 2026-04-01 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-03-31 | F-InKind | 27.7 | 2026-04-01 |
| Sukhatme Mayukh | director, officer: President & CIO | 2026-03-30 | M-Exempt | 0 | 2026-04-01 |
| Fitzgerald Meghan | director | 2026-03-26 | M-Exempt | 8.8 | 2026-03-30 |
| Fitzgerald Meghan | director | 2026-03-26 | M-Exempt | 8.8 | 2026-03-30 |
| Fitzgerald Meghan | director | 2026-03-26 | S-Sale | 27.45 | 2026-03-30 |
| Pulik Richard | officer: CFO | 2026-03-20 | F-InKind | 27.7 | 2026-03-24 |
| Humes Jennifer | officer: Chief Accounting Officer | 2026-03-20 | F-InKind | 27.7 | 2026-03-24 |
| Venker Eric | officer: President & Immunovant CEO | 2026-03-17 | M-Exempt | 3.85 | 2026-03-19 |
| Venker Eric | officer: President & Immunovant CEO | 2026-03-17 | M-Exempt | 3.85 | 2026-03-19 |
| Venker Eric | officer: President & Immunovant CEO | 2026-03-17 | S-Sale | 28.24 | 2026-03-19 |
| Epperly Melissa B, | director | 2026-03-16 | S-Sale | 28.68 | 2026-03-18 |
| Pulik Richard | officer: CFO | 2026-02-20 | F-InKind | 27.15 | 2026-02-24 |
| Venker Eric | officer: President & Immunovant CEO | 2026-02-20 | F-InKind | 27.15 | 2026-02-24 |
| Torti Frank | officer: President and Vant Chair | 2026-02-19 | M-Exempt | 3.85 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-20 | M-Exempt | 3.85 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-23 | M-Exempt | 3.85 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-19 | S-Sale | 27.42 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-20 | S-Sale | 27.15 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-23 | S-Sale | 27.51 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-19 | M-Exempt | 3.85 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-20 | M-Exempt | 3.85 | 2026-02-23 |
| Torti Frank | officer: President and Vant Chair | 2026-02-23 | M-Exempt | 3.85 | 2026-02-23 |
| Venker Eric | officer: President & Immunovant CEO | 2026-02-13 | M-Exempt | 3.85 | 2026-02-18 |
| Venker Eric | officer: President & Immunovant CEO | 2026-02-13 | M-Exempt | 3.85 | 2026-02-18 |
| Venker Eric | officer: President & Immunovant CEO | 2026-02-13 | S-Sale | 26.49 | 2026-02-18 |
| MANCHESTER KEITH S | director | 2026-02-11 | S-Sale | 26.67 | 2026-02-13 |
| MANCHESTER KEITH S | director | 2026-02-12 | S-Sale | 26.72 | 2026-02-13 |
| MANCHESTER KEITH S | director | 2026-02-12 | S-Sale | 26.76 | 2026-02-13 |
| MANCHESTER KEITH S | director | 2026-02-13 | S-Sale | 26.49 | 2026-02-13 |
| MANCHESTER KEITH S | director | 2026-02-13 | S-Sale | 26.5 | 2026-02-13 |
| Gold Daniel Allen | director | 2026-02-11 | S-Sale | 26.67 | 2026-02-13 |
| Gold Daniel Allen | director | 2026-02-12 | S-Sale | 26.72 | 2026-02-13 |
| Gold Daniel Allen | director | 2026-02-12 | S-Sale | 26.76 | 2026-02-13 |
| Gold Daniel Allen | director | 2026-02-13 | S-Sale | 26.49 | 2026-02-13 |
| Gold Daniel Allen | director | 2026-02-13 | S-Sale | 26.5 | 2026-02-13 |
| QVT Financial LP | other: Director by Deputization | 2026-02-11 | S-Sale | 26.67 | 2026-02-13 |
| QVT Financial LP | other: Director by Deputization | 2026-02-12 | S-Sale | 26.72 | 2026-02-13 |